These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

182 related articles for article (PubMed ID: 10918201)

  • 1. Bcl-xl antisense treatment induces apoptosis in breast carcinoma cells.
    Simões-Wüst AP; Olie RA; Gautschi O; Leech SH; Häner R; Hall J; Fabbro D; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 Aug; 87(4):582-90. PubMed ID: 10918201
    [TBL] [Abstract][Full Text] [Related]  

  • 2. A novel bispecific antisense oligonucleotide inhibiting both bcl-2 and bcl-xL expression efficiently induces apoptosis in tumor cells.
    Zangemeister-Wittke U; Leech SH; Olie RA; Simões-Wüst AP; Gautschi O; Luedke GH; Natt F; Häner R; Martin P; Hall J; Nalin CM; Stahel RA
    Clin Cancer Res; 2000 Jun; 6(6):2547-55. PubMed ID: 10873111
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Activity of a novel bcl-2/bcl-xL-bispecific antisense oligonucleotide against tumors of diverse histologic origins.
    Gautschi O; Tschopp S; Olie RA; Leech SH; Simões-Wüst AP; Ziegler A; Baumann B; Odermatt B; Hall J; Stahel RA; Zangemeister-Wittke U
    J Natl Cancer Inst; 2001 Mar; 93(6):463-71. PubMed ID: 11259472
    [TBL] [Abstract][Full Text] [Related]  

  • 4. A functionally improved locked nucleic acid antisense oligonucleotide inhibits Bcl-2 and Bcl-xL expression and facilitates tumor cell apoptosis.
    Simões-Wüst AP; Hopkins-Donaldson S; Sigrist B; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Oligonucleotides; 2004; 14(3):199-209. PubMed ID: 15625915
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Bcl-2/bcl-xL bispecific antisense treatment sensitizes breast carcinoma cells to doxorubicin, paclitaxel and cyclophosphamide.
    Simões-Wüst AP; Schürpf T; Hall J; Stahel RA; Zangemeister-Wittke U
    Breast Cancer Res Treat; 2002 Nov; 76(2):157-66. PubMed ID: 12452453
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A novel antisense oligonucleotide inhibiting several antiapoptotic Bcl-2 family members induces apoptosis and enhances chemosensitivity in androgen-independent human prostate cancer PC3 cells.
    Yamanaka K; Rocchi P; Miyake H; Fazli L; Vessella B; Zangemeister-Wittke U; Gleave ME
    Mol Cancer Ther; 2005 Nov; 4(11):1689-98. PubMed ID: 16275990
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Trastuzumab down-regulates Bcl-2 expression and potentiates apoptosis induction by Bcl-2/Bcl-XL bispecific antisense oligonucleotides in HER-2 gene--amplified breast cancer cells.
    Milella M; Trisciuoglio D; Bruno T; Ciuffreda L; Mottolese M; Cianciulli A; Cognetti F; Zangemeister-Wittke U; Del Bufalo D; Zupi G
    Clin Cancer Res; 2004 Nov; 10(22):7747-56. PubMed ID: 15570009
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Bcl-2 and bcl-xL antisense oligonucleotides induce apoptosis in melanoma cells of different clinical stages.
    Olie RA; Hafner C; Küttel R; Sigrist B; Willers J; Dummer R; Hall J; Stahel RA; Zangemeister-Wittke U
    J Invest Dermatol; 2002 Mar; 118(3):505-12. PubMed ID: 11874491
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Combined targeted inhibition of bcl-2, bcl-XL, epidermal growth factor receptor, and protein kinase A type I causes potent antitumor, apoptotic, and antiangiogenic activity.
    Tortora G; Caputo R; Damiano V; Caputo R; Troiani T; Veneziani BM; De Placido S; Bianco AR; Zangemeister-Wittke U; Ciardiello F
    Clin Cancer Res; 2003 Feb; 9(2):866-71. PubMed ID: 12576461
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Analysis of ribosyl-modified, mixed backbone analogs of a bcl-2/bcl-xL antisense oligonucleotide.
    Olie RA; Hall J; Natt F; Stahel RA; Zangemeister-Wittke U
    Biochim Biophys Acta; 2002 Jun; 1576(1-2):101-9. PubMed ID: 12031489
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Antisense oligonucleotides directed at the bcl-xl gene product augment chemotherapy response in mesothelioma.
    Ozvaran MK; Cao XX; Miller SD; Monia BA; Hong WK; Smythe WR
    Mol Cancer Ther; 2004 May; 3(5):545-50. PubMed ID: 15141012
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Down-regulation of Bcl-2 and Bcl-xL expression with bispecific antisense treatment in glioblastoma cell lines induce cell death.
    Jiang Z; Zheng X; Rich KM
    J Neurochem; 2003 Jan; 84(2):273-81. PubMed ID: 12558990
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53-Independent induction of apoptosis in human melanoma cells by a bcl-2/bcl-xL bispecific antisense oligonucleotide.
    Strasberg Rieber M; Zangemeister-Wittke U; Rieber M
    Clin Cancer Res; 2001 May; 7(5):1446-51. PubMed ID: 11350916
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Induction of apoptosis and chemosensitization of mesothelioma cells by Bcl-2 and Bcl-xL antisense treatment.
    Hopkins-Donaldson S; Cathomas R; Simões-Wüst AP; Kurtz S; Belyanskaya L; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2003 Aug; 106(2):160-6. PubMed ID: 12800189
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Chemosensitization of bladder carcinoma cells by bcl-xL antisense oligonucleotides.
    Lebedeva I; Raffo A; Rando R; Ojwang J; Cossum P; Stein CA
    J Urol; 2001 Aug; 166(2):461-9. PubMed ID: 11458048
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Antisense Bcl-xl down-regulation switches the response to topoisomerase I inhibition from senescence to apoptosis in colorectal cancer cells, enhancing global cytotoxicity.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Clin Cancer Res; 2003 Jul; 9(7):2856-65. PubMed ID: 12855666
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Induction of apoptosis in lung-cancer cells following bcl-xL anti-sense treatment.
    Leech SH; Olie RA; Gautschi O; Simões-Wüst AP; Tschopp S; Häner R; Hall J; Stahel RA; Zangemeister-Wittke U
    Int J Cancer; 2000 May; 86(4):570-6. PubMed ID: 10797273
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Bcl-xL in prostate cancer cells: effects of overexpression and down-regulation on chemosensitivity.
    Lebedeva I; Rando R; Ojwang J; Cossum P; Stein CA
    Cancer Res; 2000 Nov; 60(21):6052-60. PubMed ID: 11085527
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Enhanced oxaliplatin-induced apoptosis following antisense Bcl-xl down-regulation is p53 and Bax dependent: Genetic evidence for specificity of the antisense effect.
    Hayward RL; Macpherson JS; Cummings J; Monia BP; Smyth JF; Jodrell DI
    Mol Cancer Ther; 2004 Feb; 3(2):169-78. PubMed ID: 14985457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [The effects of antisense oligonucleotides bcl-2/bcl-xl and bcl-2 on proliferation and apoptosis of breast cancer cells].
    Ma C; Xie JW; Kuang AR; Huang R; Tang GS
    Sichuan Da Xue Xue Bao Yi Xue Ban; 2009 Sep; 40(5):780-3. PubMed ID: 19950582
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.